

APB043Hu01 100µg

Active Tumor Necrosis Factor Receptor Superfamily, Member 7 (TNFRSF7)
Organism Species: Homo sapiens (Human)

Instruction manual

FOR IN VITRO USE AND RESEARCH USE ONLY
NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

1th Edition (Apr. 2016)

#### [PROPERTIES]

Source: Prokaryotic expression.

Host: E. coli

Residues: Ser19~Asp188 Tags: N-terminal His-tag

**Purity: >95%** 

Buffer Formulation: 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl

and 5% trehalose.

**Applications:** Cell culture; Activity Assays; In vivo assays.

(May be suitable for use in other assays to be determined by the end user.)

Predicted isoelectric point: 7.2

Predicted Molecular Mass: 20.1kDa

Accurate Molecular Mass: 20kDa as determined by SDS-PAGE reducing conditions.

#### [USAGE]

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

### [STORAGE AND STABILITY]

**Storage:** Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.



**Stability Test:** The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

#### [SEQUENCE]

SA TPAPKSCPER HYWAQGKLCC QMCEPGTFLV KDCDQHRKAA QCDPCIPGVS FSPDHHTRPH CESCRHCNSG LLVRNCTITA NAECACRNGW QCRDKECTEC DPLPNPSLTA RSSQALSPHP QPTHLPYVSE MLEARTAGHM QTLADFRQLP ARTLSTHWPP QRSLCSSD

#### [ACTIVITY]

TNFRSF7 (Tumor necrosis factor receptor superfamily member 7), also known as CD27 antigen, is a member of the TNF-receptor superfamily. This receptor is thought to be involved in tumor necrosis factor-activated receptor activity by binding with TNFs. Thus, a binding ELISA assay was conducted to detect the association of TNFRSF7 with TNFa. Briefly, recombinant human TNFRSF7 were diluted serially in PBS with 0.01%BSA (pH 7.4). Duplicate samples of 100uL were then transferred to TNFa-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-TNFRSF7 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of TNFRSF7 with TNFa was shown in Figure 1 and this effect was in a dose dependent manner.




Figure 1. The binding activity of TNFRSF7 with TNFa.

## [ IDENTIFICATION ]




Figure 2. SDS-PAGE

Sample: Active recombinant TNFRSF7, Human

# Coud-Clone Corp.




Figure 3. Western Blot

Sample: Recombinant TNFRSF7, Human;

Antibody: Rabbit Anti-Human TNFRSF7 Ab (PAB043Hu01)